-
Who are the "excellent students" in the innovative drug industry in 2021?
Time of Update: 2022-02-21
A number of firstin class drugs entered China, and 6 "excellent students" became leaders Among the 68 innovative drugs approved in 2021, there are 6 new drugs with firstinclass mechanisms (see Table 2).
4. A number of improved new chemical drugs have been approved, and 2 "excellent students" are "cross-border experts"4.
-
What are the new drugs approved by the FDA in 2021?
Time of Update: 2022-02-21
Summary of CDER Approved Drugs in 2021 Additional additions to further approvals by the FDA's Center for Biologics Evaluation and Research (CBER) include landmark mRNA vaccines and CAR-T cell products (Table 2) .
-
Industry research: What is the best development model for CRC/SMO?
Time of Update: 2022-02-21
, the researcher visited 15 SMO companies with 300 to 2000 people in CRC and many drug clinical trial institutions, trying to understand from the macro to the micro.
-
2022 Cell Gene Therapy Track: How to Accelerate Technological Iteration
Time of Update: 2022-02-20
Although still in the early stages of development, the broad pipeline and possible mechanisms of action make in vivo gene therapy a potentially attractive technological approach in the future treatment of solid tumors .
-
The Yangtze River, Qilu, Chia Tai Tianqing... Harvest!
Time of Update: 2022-02-20
In the whole year of 2021, a total of 20 generic drugs (29 product specifications) of Sino Biopharmaceuticals were approved for marketing, and the number of approved varieties decreased compared with 2020 (23) .
-
5 big questions for gene therapy in 2022
Time of Update: 2022-02-20
Four years ago, a small Philadelphia biotech company won FDA approval for the first gene therapy to treat an inherited retinal disease that can lead to blindness, part of a decades-long effort to find ways to correct errors in DNA.
-
Nearly 80 domestic dual-resistance models flooded into the market of over 50 billion!
Time of Update: 2022-02-20
On January 5, Pharmaco announced that its self-developed Kadeninumab (AK104) combined with AK112 double antibody phase Ib/II clinical trial application was approved by NMPA, with or without chemotherapy for the treatment of advanced non-small cell lung cancer.
-
Bristol-Myers Squibb's 'Rottercept' to be approved for beta thalassemia
Time of Update: 2022-02-20
β-thalassemia major is a chronic progressive hemolytic anemia, and patients need to rely on lifelong blood transfusion, iron removal therapy, or hematopoietic stem cell transplantation to maintain life .
-
12 Class 1 new drugs have been approved for clinical use!
Time of Update: 2022-02-20
According to an earlier press release from Bangshun Pharmaceuticals, OB756 is an oral selective JAK2 inhibitor independently developed by the company, which can exert therapeutic effects by targeting the kinase activity of JAK2 V617F and blocking the JAK/STAT signaling pathway .
-
A collection of the latest trends and future plans for the JPM conference review of health care companies
Time of Update: 2022-02-20
But the company isn't planning to slow down, and expects to grow another 15% in 2022, helped by a slew of new products and partnerships -- including Grail's multi-cancer early-detection blood test, as well as adding long reads in the future Sequencing function to its current short read machine .
-
The seventh batch of centralized procurement will start reporting this week!
Time of Update: 2022-02-20
From: Joint Acquisition Document The list of specifications in the document is as follows: Attachment: The Seventh Batch of National Procurement Regulations + Enterprise Review List Data for this inventory is from the Insight database as of January 21, 2022 .
-
Moderna plans to launch a three-in-one vaccine for COVID-19/flu/RSV
Time of Update: 2022-02-20
According to the latest news, Moderna is actively preparing to launch a three-in-one vaccine by fall 2023, which will be effective against both COVID-19 and influenza, and also prevent respiratory syncytial virus (RSV) infection .
-
Courier Expert Opinion: A Critical Factor in Safeguarding the Success of the FDA's Accelerated Approval Program
Time of Update: 2022-02-20
Completing confirmatory studies as quickly as possible is critical to the success of accelerated approval programs , a number of regulatory and industry experts said at CERSI’s Innovations in Regulatory Science Summit recently .
-
250 million US dollars of counterfeit AIDS drugs flowed into the US market, and Gilead revealed the shady scene after half a year
Time of Update: 2022-02-20
In two years, 85,247 bottles of counterfeit versions of the two drugs were sold, worth about $250 million; In the first half of 2021, the Food and Drug Administration investigated and dealt with 3,958 cases of production, sale and use of counterfeit and inferior drugs, worth 38.
-
In-depth inventory: An article takes you to understand gene editing technology
Time of Update: 2022-02-20
As shown in Figure 1, the main structure of TALE protein is divided into three parts, including: the tandem repeat sequence of the central domain (Repeat domain), the nuclear localization signal and the acidic transcriptional activation domain, wherein the tandem repeat sequence of the central domain is TALENs technology specifically recognizes regions of DNA sequences .
-
Preliminary exploration of new drug conjugates: PDC and ISAC have different situations
Time of Update: 2022-02-20
On September 13, 2021, the pioneering company Silverback Therapeutics announced the interim Phase I/Ib clinical data of its new immune-agonist ADC drug SBT6050 at the ESMO meeting.
-
Gilead claims $250 million in counterfeit HIV drugs flowed into U.S. market in 2 years
Time of Update: 2022-02-20
According to a report released by Gilead recently, up to $250 million of counterfeit HIV drugs Biktarvy and Descovy were sold to American consumers in major pharmacies in the United States in the past two years .
-
Cinova URAT1 new gout drug pivotal Phase II data announced, aiming at Best-in-class
Time of Update: 2022-02-20
In 2019, XNW3009 conducted the first clinical study in Australia; in March 2021, Sinovate announced that XNW3009 tablets can reduce uric acid in patients with hyperuricemia (with or without gout) on the drug clinical trial registration and information publicity platform A multicenter, randomized, double-blind, benzbromarone-controlled, parallel-group phase II clinical study of efficacy and safety .
-
Monthly income exceeded 500 million!
Time of Update: 2022-02-20
You may have seen profitable companies, but you must have never seen such a profitable business - at the JPMorgan Healthcare Conference, the British digital medical veteran Babylon Health (Babylon fo
-
Focus on drug targets: TNF-α inhibitor wars, who is in charge of ups and downs?
Time of Update: 2022-02-20
Yisaipu (recombinant human type II tumor necrosis factor receptor antibody fusion protein) is the first fully human antibody drug on the market in China and the first TNF-α inhibitor on the market in the field of rheumatism in China.
